株式会社ジーエヌアイグループ 2025年12月期 第3四半期 決算説明資料

This document is the Q3 financial results presentation for the fiscal year ending December 2025 of GNI Group Ltd. It includes an overview of the company, segment performance, financial highlights, and forecasts for the current fiscal year. The document emphasizes the strong sales performance of the leading product, Etuary®, which has achieved record sales. It also discusses the development status of the liver fibrosis treatment candidate F351 and the market environment for Etorel®. Future performance outlooks and promotional strategies for new products are addressed, highlighting the company's aim for sustainable growth and maximizing shareholder value.